What is Eternatear?
EternaTear operates at the intersection of biotechnology and ophthalmology, specializing in the development of next-generation artificial tears. By engineering a unique mechanism that mimics the composition and longevity of natural human tears, the company addresses the significant unmet needs of patients suffering from chronic dry eye syndrome. Unlike conventional over-the-counter solutions that require frequent application, EternaTear's innovative delivery system provides extended relief, effectively positioning the firm as a disruptive force in the multi-billion dollar ocular surface disease market. The company's commitment to pioneering research and clinical efficacy distinguishes it from traditional pharmaceutical incumbents, offering a scalable solution for a growing global patient demographic.
How much funding has Eternatear raised?
Eternatear has raised a total of $4.9M across 1 funding round:
Series A
$4.9M
Series A (2020): $4.9M with participation from Deep Work Capital, Keiretsu Forum, Band of Angels, Carolina Angel Network LLC, Duke Angel Network, and Keiretsu Capital
Key Investors in Eternatear
Keiretsu Forum
Keiretsu Forum is a prominent global investment community that connects angel investors, venture capitalists, and institutional partners with high-growth startups.
Band of Angels
As Silicon Valley's oldest angel investment group, this organization leverages the deep technical and executive expertise of its members to support early-stage life science and high-tech ventures.
Keiretsu Capital
Keiretsu Capital serves as the investment arm of the Keiretsu ecosystem, providing strategic financial backing to companies that demonstrate significant market potential and innovation.
What's next for Eternatear?
Following this major enterprise-level funding, EternaTear is poised to transition from its initial development phase into a more aggressive commercialization and clinical validation strategy. The capital will likely be deployed to scale manufacturing capabilities, expand clinical trial footprints, and navigate the regulatory pathways necessary for broader market adoption. As the company matures, the focus will shift toward establishing strategic partnerships with healthcare providers and distribution networks to ensure its therapeutic solutions reach the target patient population efficiently. This growth trajectory suggests a long-term objective of setting a new standard of care in the dry eye treatment landscape, potentially attracting further interest from larger life sciences conglomerates seeking to bolster their ophthalmic portfolios.
See full Eternatear company page
